BioRestorative Therapies Announces SBIR Phase I Grant to Explore Therapeutic Effects of ThermoStem Targeting Polycystic Ovarian Syndrome As an Indication

BioRestorative Therapies Announces SBIR Phase I Grant to Explore Therapeutic Effects of ThermoStem Targeting Polycystic Ovarian Syndrome As an Indication

BioRestorative Therapies, Inc. (‘BioRestorative’, ‘BRTX’ or the ‘Company’) (NASDAQ: BRTX), a clinical-stage company focused on stem cell-based therapies, announced today that it has received a Innovation Research for Small Businesses (SBIR) Grant Phase I of the Eunice Kennedy Shriver National Institute of Child Health and Human Development of National Institutes of Health. This collaborative research … Read more

BioRestorative Therapies Enters into Agreement with Regenexx, Granting BRTX Exclusive License Rights to Intellectual Property Related to the Development and Commercialization of its BRTX-100 Disc Program to Treat Chronic Lumbar Disc Disease

BioRestorative Therapies Enters into Agreement with Regenexx, Granting BRTX Exclusive License Rights to Intellectual Property Related to the Development and Commercialization of its BRTX-100 Disc Program to Treat Chronic Lumbar Disc Disease

BioRestorative Therapies, Inc. (‘BioRestorative’ or the ‘Company’) (NASDAQ: BRTX), a clinical-stage company focused on stem cell-based therapies, today announced an agreement with Regenexx, LLC pursuant to which the license rights granted by Regenexx to the Company for intellectual property developed to treat chronic lumbar disc disease have become exclusive. The intellectual property now exclusively licensed … Read more

DKSH: Lupine and DKSH sign an exclusive license and supply agreement to commercialize five biosimilars in the Philippines

DKSH: Lupine and DKSH sign an exclusive license and supply agreement to commercialize five biosimilars in the Philippines

Press release Lupine and DKSH sign an exclusive license and supply agreement to commercialize five biosimilars in the Philippines DKSH and Lupine have signed an exclusive license and supply agreement to commercialize five of Alvotech’s high-quality biosimilars in the Philippines. Philippines, August 25, 2022 – DKSH Business Unit Healthcare, a leading partner … Read more

BioRestorative Therapies Enters into Agreement with Regenexx, Granting BRTX Exclusive License Rights to Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease

BioRestorative Therapies Enters into Agreement with Regenexx, Granting BRTX Exclusive License Rights to Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease

— Intellectual property provides a cell-based therapeutic platform designed to target all avascular sites— MELVILLE, New York, Dec. 5, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorer” or the “Company”) (NASDAQ: BRTX)a clinical-stage company focused on stem cell-based therapies, today announced an agreement with Regenexx, LLC pursuant to which the license rights granted by Regenexx … Read more

Adaptive Biotechnologies announces the launch of clonoSEQ® to assess minimal residual disease (MRD) in patients with diffuse large B-cell lymphoma (DLBCL) using circulating tumor DNA (ctDNA)

Adaptive Biotechnologies announces the launch of clonoSEQ® to assess minimal residual disease (MRD) in patients with diffuse large B-cell lymphoma (DLBCL) using circulating tumor DNA (ctDNA)

clonoSEQ is the first and only Medicare-covered DLBCL MRD test across all lines of therapy, treatment regimens, and time points Adaptive now accepts blood samples from DLBCL patients in ctDNA-stabilizing Streck® tubes SEATTLE, December 01, 2022 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of … Read more

Aquestive Therapeutics Announces Publication of Crossover Study of Dietary Effect of Diazepam Nasal Spray in Epilepsy

Aquestive Therapeutics Announces Publication of Crossover Study of Dietary Effect of Diazepam Nasal Spray in Epilepsy

Peer-reviewed data indicate that food significantly decreases and delays the absorption of diazepam dosed via nasal spray WARREN, NJ, Nov. 29, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company that advances current standards of care to solve patient problems by simplifying delivery methods complexes, announced today the publication of a pharmacokinetic … Read more

ALX Oncology names Scott Garland to its board of directors

ALX Oncology names Scott Garland to its board of directors

SOUTH SAN FRANCISCO, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing point-blocking therapies of control CD47 way, today announced the appointment of Scott Garland to its Board of Directors (the “Board”) effective November 29, 2022. With more than 30 years of knowledge of … Read more

JBM Healthcare Announces Interim Results for Fiscal Year 2023

JBM Healthcare Announces Interim Results for Fiscal Year 2023

HONG KONG, November 25, 2022 – (ACN Newswire) – – JBM (medical care) limited (“JBM Health” or the “Group”; Stock Code: 2161), a leading marketer and distributor of brand name healthcare products in Hong Kongtoday announced the Group’s intermediate results for the semester ended September 30, 2022 (the “Reporting Period”). KEY POINTS — Period-over-period revenue … Read more

Innovative treatment for chemotherapy hair loss will be presented at Stora Aktiedagen

Innovative treatment for chemotherapy hair loss will be presented at Stora Aktiedagen

dignitana CEO Catarina Mård Löwenadler will speak at Aktiespararna Stora Aktiedagen on November 29 in Stockholm. Ms. Löwenadler’s 20-minute presentation begins at 1830 CE and it will be broadcast live. Event participants will have the opportunity to ask questions after your presentation. “Increased demand and high customer satisfaction continue to drive of dignitana increase. We … Read more

Kintor Pharmaceutical: Pharma announced the completion of the Phase I trial of the world’s first PROTAC compound (GT20029) for topical use

Kintor Pharmaceutical: Pharma announced the completion of the Phase I trial of the world’s first PROTAC compound (GT20029) for topical use

Suzhou, November 24, 2022: Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biologic therapies, today announced the key results of its Phase I clinical trial. of GT20029 for the treatment of androgenetic alopecia (AGA) and acne in China, which demonstrated the good safety, tolerability and pharmacokinetics of … Read more